三阴乳腺癌的分子分型及靶向、免疫和中药治疗研究进展
Research Progress on Molecular Subtyping, Targeted Therapy, Immunotherapy, and Traditional Chinese Medicine-Based Interventions for Triple-Negative Breast Cancer
DOI: 10.12677/wjcr.2026.162013, PDF,   
作者: 张仕玉*, 刘 泉, 刘嘉敏, 李 霁#：昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明；云南省现代生物医药产业学院，云南 昆明；刘 勤#：云南省食品药品监督检验研究院，云南 昆明
关键词: 三阴乳腺癌；分子分型；信号通路；靶向治疗；免疫治疗；中药联合其他药物；Triple-Negative Breast Cancer； Molecular Subtyping； Signaling Pathways； Targeted Therapy； Immunotherapy； Traditional Chinese Medicine Combined with Other Drugs
摘要: 三阴性乳腺癌(TNBC)是乳腺癌的一种高度侵袭性亚型，负表达雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (HER2)。化疗是TNBC患者的主要全身性治疗手段，但其疗效不尽如人意，且常伴随显著的治疗相关毒副作用。当务之急是寻找更有效的疗法。根据TNBC中表达的特定分子和信号通路，已经出现了多种靶向治疗策略，包括PI3K/AKT/mTOR抑制剂、表皮生长因子受体抑制剂、Notch抑制剂、聚ADP-核糖聚合酶抑制剂和AR抑制剂。本文系统梳理了三阴性乳腺癌(TNBC)的分子分型，免疫治疗、靶向治疗和中药联合其他药物等多种治疗策略，旨在为TNBC个体化治疗的未来发展提供参考与方向。
Abstract: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Chemotherapy remains the primary systemic treatment for TNBC patients; however, its efficacy is often suboptimal and accompanied by significant treatment-related toxicities. There is a pressing need to develop more effective therapeutic approaches. In recent years, various targeted therapeutic strategies have emerged based on specific molecules and signaling pathways implicated in TNBC, including inhibitors of PI3K/AKT/mTOR, epidermal growth factor receptor, Notch, poly ADP-ribose polymerase (PARP), and androgen receptor (AR). This article systematically reviews the molecular subtypes of triple-negative breast cancer (TNBC), as well as various treatment strategies for TNBC, including immunotherapy, targeted therapy, and the combination of traditional Chinese medicine with other drugs, which aims to offer insights and direction for the future development of personalized therapy for TNBC.
文章引用：张仕玉, 刘泉, 刘嘉敏, 刘勤, 李霁. 三阴乳腺癌的分子分型及靶向、免疫和中药治疗研究进展[J]. 世界肿瘤研究, 2026, 16(2): 113-125. https://doi.org/10.12677/wjcr.2026.162013

参考文献

[1] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. [Google Scholar] [CrossRef] [PubMed]
[2] Yang, C.-Q., Liu, J., Zhao, S.-Q., Zhu, K., Gong, Z.-Q., Xu, R., et al. (2020) Recent Treatment Progress of Triple Negative Breast Cancer. Progress in Biophysics and Molecular Biology, 151, 40-53. [Google Scholar] [CrossRef] [PubMed]
[3] Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L.A., Minihan, A., et al. (2022) Breast Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 524-541. [Google Scholar] [CrossRef] [PubMed]
[4] Bianchini, G., Balko, J.M., Mayer, I.A., Sanders, M.E. and Gianni, L. (2016) Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease. Nature Reviews Clinical Oncology, 13, 674-690. [Google Scholar] [CrossRef] [PubMed]
[5] Fu, A.Z., Kuang, Y., Fazeli, M.S., Kumar, N. and Davis, C. (2019) Current Treatment Landscape in Triple Negative Breast Cancer: A Systematic Literature Review. Annals of Oncology, 30, iii55-iii56. [Google Scholar] [CrossRef] 
[6] Salpeter, S.R., Malter, D.S., Luo, E.J., Lin, A.Y. and Stuart, B. (2012) Systematic Review of Cancer Presentations with a Median Survival of Six Months or Less. Journal of Palliative Medicine, 15, 175-185. [Google Scholar] [CrossRef] [PubMed]
[7] Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U. and Harbeck, N. (2009) Triple-negative Breast Cancer—Current Status and Future Directions. Annals of Oncology, 20, 1913-1927. [Google Scholar] [CrossRef] [PubMed]
[8] Zhao, S., Ma, D., Xiao, Y., Jiang, Y. and Shao, Z. (2018) Clinicopathologic Features and Prognoses of Different Histologic Types of Triple-Negative Breast Cancer: A Large Population-Based Analysis. European Journal of Surgical Oncology, 44, 420-428. [Google Scholar] [CrossRef] [PubMed]
[9] Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., et al. (2011) Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. Journal of Clinical Investigation, 121, 2750-2767. [Google Scholar] [CrossRef] [PubMed]
[10] Burstein, M.D., Tsimelzon, A., Poage, G.M., Covington, K.R., Contreras, A., Fuqua, S.A.W., et al. (2015) Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research, 21, 1688-1698. [Google Scholar] [CrossRef] [PubMed]
[11] Lehmann, B.D., Jovanović, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., et al. (2016) Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLOS ONE, 11, e0157368. [Google Scholar] [CrossRef] [PubMed]
[12] Liu, Y., Jiang, Y., Xu, X., Yu, K., Jin, X., Hu, X., et al. (2016) Comprehensive Transcriptome Analysis Identifies Novel Molecular Subtypes and Subtype-Specific RNAs of Triple-Negative Breast Cancer. Breast Cancer Research, 18, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[13] Hossain, F., Majumder, S., David, J. and Miele, L. (2021) Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. Cancers, 13, Article 3739. [Google Scholar] [CrossRef] [PubMed]
[14] Han, Y., Yu, X., Li, S., Tian, Y. and Liu, C. (2020) New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Frontiers in Oncology, 10, Article 578095. [Google Scholar] [CrossRef] [PubMed]
[15] Bianchini, G., De Angelis, C., Licata, L. and Gianni, L. (2021) Treatment Landscape of Triple-Negative Breast Cancer—Expanded Options, Evolving Needs. Nature Reviews Clinical Oncology, 19, 91-113. [Google Scholar] [CrossRef] [PubMed]
[16] Lu, B., Natarajan, E., Balaji Raghavendran, H.R. and Markandan, U.D. (2023) Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review. Technology in Cancer Research & Treatment, 22, 1-10.
[17] Shi, Y., Jin, J., Ji, W. and Guan, X. (2018) Therapeutic Landscape in Mutational Triple Negative Breast Cancer. Molecular Cancer, 17, Article No. 99. [Google Scholar] [CrossRef] [PubMed]
[18] Garmpis, N., Damaskos, C., Garmpi, A., Nikolettos, K., Dimitroulis, D., Diamantis, E., et al. (2020) Molecular Classification and Future Therapeutic Challenges of Triple-Negative Breast Cancer. In Vivo, 34, 1715-1727. [Google Scholar] [CrossRef] [PubMed]
[19] Ellis, H. and Ma, C.X. (2019) PI3K Inhibitors in Breast Cancer Therapy. Current Oncology Reports, 21, Article No. 110. [Google Scholar] [CrossRef] [PubMed]
[20] Thorsson, V., Gibbs, D.L., Brown, S.D., et al. (2018) The Immune Landscape of Cancer. Immunity, 48, 812-830.e14.
[21] Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., et al. (2018) Triple Negative Breast Cancer: Key Role of Tumor-Associated Macrophages in Regulating the Activity of Anti-PD-1/PD-L1 Agents. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1869, 78-84. [Google Scholar] [CrossRef] [PubMed]
[22] Yoo, T.K., Kang, J., Lee, A., et al. (2022) A Triple-Negative Breast Cancer Surrogate Subtype Classification that Correlates with Gene Expression Subtypes. Breast Cancer Research and Treatment, 191, 599-610.
[23] Ding, Y.C., Steele, L., Warden, C., Wilczynski, S., Mortimer, J., Yuan, Y., et al. (2019) Molecular Subtypes of Triple-Negative Breast Cancer in Women of Different Race and Ethnicity. Oncotarget, 10, 198-208. [Google Scholar] [CrossRef] [PubMed]
[24] Anestis, A., Sarantis, P., Theocharis, S., Zoi, I., Tryfonopoulos, D., Korogiannos, A., et al. (2019) Estrogen Receptor Beta Increases Sensitivity to Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer. Journal of Cancer Research and Clinical Oncology, 145, 1221-1233. [Google Scholar] [CrossRef] [PubMed]
[25] Marra, A., Trapani, D., Viale, G., Criscitiello, C. and Curigliano, G. (2020) Practical Classification of Triple-Negative Breast Cancer: Intratumoral Heterogeneity, Mechanisms of Drug Resistance, and Novel Therapies. npj Breast Cancer, 6, Article No. 54. [Google Scholar] [CrossRef] [PubMed]
[26] Jiang, Y.Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.e5.
[27] Rigiracciolo, D.C., Nohata, N., Lappano, R., Cirillo, F., Talia, M., Scordamaglia, D., et al. (2020) IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. Cells, 9, Article 1010. [Google Scholar] [CrossRef] [PubMed]
[28] Fancellu, A., Houssami, N., Sanna, V., Porcu, A., Ninniri, C. and Marinovich, M.L. (2021) Outcomes after Breast-Conserving Surgery or Mastectomy in Patients with Triple-Negative Breast Cancer: Meta-Analysis. British Journal of Surgery, 108, 760-768. [Google Scholar] [CrossRef] [PubMed]
[29] Pan, X., Qu, S., Jiang, Y. and Zhu, X. (2015) Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. Breast Care, 10, 413-416. [Google Scholar] [CrossRef] [PubMed]
[30] Kumar, P. and Aggarwal, R. (2016) An Overview of Triple-Negative Breast Cancer. Archives of Gynecology and Obstetrics, 293, 247-269. [Google Scholar] [CrossRef] [PubMed]
[31] Dragun, A.E., Pan, J., Rai, S.N., Kruse, B. and Jain, D. (2011) Locoregional Recurrence in Patients with Triple-Negative Breast Cancer. American Journal of Clinical Oncology, 34, 231-237. [Google Scholar] [CrossRef] [PubMed]
[32] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Clarke, M., Coates, A.S., Darby, S.C., Davies, C., Gelber, R.D., et al. (2008) Adjuvant Chemotherapy in Oestrogen-Receptor-Poor Breast Cancer: Patient-Level Meta-Analysis of Randomised Trials. The Lancet, 371, 29-40. [Google Scholar] [CrossRef] [PubMed]
[33] Weng, W., Feng, J., Qin, H. and Ma, Y. (2014) Molecular Therapy of Colorectal Cancer: Progress and Future Directions. International Journal of Cancer, 136, 493-502. [Google Scholar] [CrossRef] [PubMed]
[34] Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A.M., Nemsadze, G., et al. (2020) Capivasertib Plus Paclitaxel versus Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38, 423-433. [Google Scholar] [CrossRef] [PubMed]
[35] Bernsdorf, M., Ingvar, C., Jörgensen, L., Tuxen, M.K., Jakobsen, E.H., Saetersdal, A., et al. (2011) Effect of Adding Gefitinib to Neoadjuvant Chemotherapy in Estrogen Receptor Negative Early Breast Cancer in a Randomized Phase II Trial. Breast Cancer Research and Treatment, 126, 463-470. [Google Scholar] [CrossRef] [PubMed]
[36] Turner, N., Lambros, M.B., Horlings, H.M., Pearson, A., Sharpe, R., Natrajan, R., et al. (2010) Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Amplicon Drivers and Potential Therapeutic Targets. Oncogene, 29, 2013-2023. [Google Scholar] [CrossRef] [PubMed]
[37] Fasching, P.A., Loibl, S., Hu, C., Hart, S.N., Shimelis, H., Moore, R., et al. (2018) BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients with Triple-Negative Breast Cancer from the Geparquinto Study. Journal of Clinical Oncology, 36, 2281-2287. [Google Scholar] [CrossRef] [PubMed]
[38] Choupani, E., Madjd, Z., Saraygord-Afshari, N., Kiani, J. and Hosseini, A. (2022) Combination of Androgen Receptor Inhibitor Enzalutamide with the CDK4/6 Inhibitor Ribociclib in Triple Negative Breast Cancer Cells. PLOS ONE, 17, e0279522. [Google Scholar] [CrossRef] [PubMed]
[39] Teo, Z.L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C.P., et al. (2017) Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. Cancer Research, 77, 6340-6352. [Google Scholar] [CrossRef] [PubMed]
[40] Cretella, D., Ravelli, A., Fumarola, C., La Monica, S., Digiacomo, G., Cavazzoni, A., et al. (2018) The Anti-Tumor Efficacy of CDK4/6 Inhibition Is Enhanced by the Combination with PI3K/AKT/mTOR Inhibitors through Impairment of Glucose Metabolism in TNBC Cells. Journal of Experimental & Clinical Cancer Research, 37, Article No. 72. [Google Scholar] [CrossRef] [PubMed]
[41] Sharma, A., Paranjape, A.N., Rangarajan, A. and Dighe, R.R. (2012) A Monoclonal Antibody against Human Notch1 Ligand-Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem-Like Cells. Molecular Cancer Therapeutics, 11, 77-86. [Google Scholar] [CrossRef] [PubMed]
[42] Lu, L., Dong, J., Wang, L., Xia, Q., Zhang, D., Kim, H., et al. (2018) Activation of STAT3 and BCL-2 and Reduction of Reactive Oxygen Species (ROS) Promote Radioresistance in Breast Cancer and Overcome of Radioresistance with Niclosamide. Oncogene, 37, 5292-5304. [Google Scholar] [CrossRef] [PubMed]
[43] Yi, M., Wu, Y., Niu, M., Zhu, S., Zhang, J., Yan, Y., et al. (2022) Anti-TGF-β/PD-l1 Bispecific Antibody Promotes T Cell Infiltration and Exhibits Enhanced Antitumor Activity in Triple-Negative Breast Cancer. Journal for ImmunoTherapy of Cancer, 10, e005543. [Google Scholar] [CrossRef] [PubMed]
[44] Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., et al. (2021) The Construction, Expression, and Enhanced Anti-Tumor Activity of YM101: A Bispecific Antibody Simultaneously Targeting TGF-β and PD-l1. Journal of Hematology & Oncology, 14, Article No. 27. [Google Scholar] [CrossRef] [PubMed]
[45] Zhang, X., Ge, X., Jiang, T., Yang, R. and Li, S. (2022) Research Progress on Immunotherapy in Triple-Negative Breast Cancer (Review). International Journal of Oncology, 61, Article No. 95. [Google Scholar] [CrossRef] [PubMed]
[46] Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 27, 450-461. [Google Scholar] [CrossRef] [PubMed]
[47] Luen, S., Virassamy, B., Savas, P., Salgado, R. and Loi, S. (2016) The Genomic Landscape of Breast Cancer and Its Interaction with Host Immunity. The Breast, 29, 241-250. [Google Scholar] [CrossRef] [PubMed]
[48] Dill, E.A., Gru, A.A., Atkins, K.A., Friedman, L.A., Moore, M.E., Bullock, T.N., et al. (2017) PD-L1 Expression and Intratumoral Heterogeneity across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors. American Journal of Surgical Pathology, 41, 334-342. [Google Scholar] [CrossRef] [PubMed]
[49] Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H.R., et al. (2014) Prognostic and Predictive Value of PDL1 Expression in Breast Cancer. Oncotarget, 6, 5449-5464. [Google Scholar] [CrossRef] [PubMed]
[50] Guo, Y., Fan, Y. and Pei, X. (2020) Fangjihuangqi Decoction Inhibits MDA‐MB‐231 Cell Invasion in Vitro and Decreases Tumor Growth and Metastasis in Triple‐Negative Breast Cancer Xenografts Tumor Zebrafish Model. Cancer Medicine, 9, 2564-2578. [Google Scholar] [CrossRef] [PubMed]
[51] Yang, X., Li, F., Shi, Y., Wu, Y., Yang, R., Liu, X., et al. (2024) Integrated Network Pharmacology and Experimental Verification to Explore the Potential Mechanism of San Ying Decoction for Treating Triple-Negative Breast Cancer. Acta Biochimica et Biophysica Sinica, 56, Article No. 13. [Google Scholar] [CrossRef] [PubMed]
[52] Arowosegbe, M.A., Amusan, O.T., Adeola, S.A., Adu, O.B., Akinola, I.A., Ogungbe, B.F., et al. (2020) Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation. Current Drug Discovery Technologies, 17, 682-695. [Google Scholar] [CrossRef] [PubMed]
[53] Elsayed, H.E., Akl, M.R., Ebrahim, H.Y., Sallam, A.A., Haggag, E.G., Kamal, A.M., et al. (2014) Discovery, Optimization, and Pharmacophore Modeling of Oleanolic Acid and Analogues as Breast Cancer Cell Migration and Invasion Inhibitors through Targeting BRK/Paxillin/RAC1 Axis. Chemical Biology & Drug Design, 85, 231-243. [Google Scholar] [CrossRef] [PubMed]
[54] 魏亚如. 乳积方对三阴乳腺癌术后患者生存影响的回顾性研究[D]: [硕士学位论文]. 广州: 广州中医药大学, 2024.
[55] 王萌, 叶倩瑜, 张明星. 自拟化痰散结方对三阴乳腺癌新辅助化疗增敏作用的临床研究[J]. 广西中医药, 2019, 42(6): 4-7.
[56] 赵成鹏, 马贞秀, 马建萍. 自拟疏肝健脾降逆方对三阴性乳腺癌TEC化疗患者毒副反应的影响[J]. 四川中医, 2021, 39(1): 120-125.
[57] 李岚岚. 柴胡疏肝散加减治疗三阴性乳腺癌的疗效观察[J]. 实用中西医结合临床, 2017, 17(2): 47-48.
[58] 刘鑫佳. 乳积方联合槐耳颗粒治疗三阴乳腺癌的回顾性分析[D]: [硕士学位论文]. 广州: 广州中医药大学, 2020.
[59] 李珊. 抑木扶土法治疗肝郁痰凝型晚期三阴性乳腺癌的临床疗效观察[D]: [硕士学位论文]. 哈尔滨: 黑龙江中医药大学, 2014.
[60] 张红卫, 周维, 沈晓燕, 等. 扶正消癌1号方联合培美曲塞和顺铂治疗晚期三阴性乳腺癌的临床疗效[J]. 肿瘤药学, 2016, 6(5): 370-374.
[61] 张一君, 王展海. 抗癌扶正方联合化疗治疗转移性三阴性乳腺癌的临床观察[J]. 中国老年学杂志, 2021, 41(6): 1170-1173.
[62] 邱志敏, 王玲, 郑智, 等. 益气解毒方联合化疗治疗晚期三阴乳腺癌患者的效果[J]. 中国当代医药, 2020, 27(23): 92-95, 99.
[63] 郑雯. 散结消瘤方联合化疗治疗晚期三阴乳腺癌患者的临床观察[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2021.
[64] 崔永佳. 化毒三阴方干预三阴乳腺癌复发转移的临床研究及miRNA机制探讨[D]: [硕士学位论文]. 北京: 北京中医药大学, 2021.
[65] 罗楚凡, 刘宁远, 张静, 等. 蒌慈散结方防治三阴性乳腺癌复发转移的临床观察[J]. 北京中医药, 2020, 39(10): 1022-1027.
[66] 李红昌, 刘维燕, 王建法, 等. 复方斑蝥通过miR-520d/Beclin1信号轴逆转三阴乳腺癌化疗耐药的机制研究[J]. 世界科学技术-中医药现代化, 2020, 22(4): 970-977.
[67] 肖洒, 刘丽芳, 丁玲, 等. 黄芪解毒汤抗三阴性乳腺癌术后复发转移临床疗效观察[J]. 四川中医, 2017, 35(1): 153-155.
[68] 王冰, 张玉柱, 陈红风. 益气小复方抑制三阴性乳腺癌外泌体传递耐药信息的作用机制研究[J]. 上海中医药大学学报, 2018, 32(6): 50-55.
[69] 杨慧芬, 毛娟娟. 二至丸合桂枝汤对三阴性乳腺癌细胞系顺铂耐药性的调控作用[J]. 浙江中医杂志, 2021, 56(10): 703-705.
[70] 车思阳, 殷东风, 高宏, 等. 乳岩宁对三阴乳腺癌荷瘤裸鼠Notch1信号通路的作用机制[J]. 中华中医药学刊, 2024, 42(6): 50-54.
[71] 杨建波. 逍遥散联合卡培他滨治疗晚期三阴性乳腺癌的临床疗效观察[J]. 临床合理用药杂志, 2016, 9(15): 83-84.
[72] 王志光, 林丽珠. 疏肝健脾益肾中药联合化疗治疗肝郁型转移性三阴性乳腺癌患者疗效及安全性研究[J]. 中国全科医学, 2015, 18(6): 620-624.
[73] 张学理. 疏肝健脾益肾中药联合化疗治疗肝郁型转移性三阴性乳腺癌的效果分析[J]. 中国实用医药, 2015(33): 177-178.
[74] 宋小青. 柴胡疏肝散加减方治疗三阴性乳腺癌的临床研究[D]: [硕士学位论文]. 武汉: 湖北中医药大学, 2016.
[75] 郑桂兰, 李英杰, 李湘红, 等. 疏肝健脾补肾方加减对三阴乳腺癌术后复发转移及免疫功能的影响[J]. 四川中医, 2016, 34(12): 118-120.
[76] 张辰岑, 尤建良. 调脾疏肝益肾方联合化疗治疗三阴性乳腺癌术后复发患者的临床观察[J]. 上海中医药杂志, 2018, 52(9): 41-43, 50.

为你推荐